METHOD FOR CORRECTION OF INNATE AND ADAPTIVE IMMUNITY FACTORS DYSFUNCTION FOR CHRONIC RENAL FAILURE IN EXPERIMENT Russian patent published in 2017 - IPC G09B23/28 A61K31/4422 A61P13/12 

FIELD: medicine.

SUBSTANCE: starting from the 21st day of chronic renal failure simulation, calcium channel blocking amlodipine drug is administered to rats using a pipette at a dose of 0.25 mg/kg per day per animal, for 7 days. Changes in innate and adaptive immunity factors in relation to the performance of laboratory animals who do not receive amlodipine, are recorded. At that, innate immunity cell factors state normalization, phagocytosis and reactive oxygen forms generation ability, intensity of delayed hypersensitivity reaction, increasing of theantibody-forming cells number in the spleen, are established.

EFFECT: method application expands information on the chronic renal failure pathogenesis mechanisms, does not require scarce supplies, is available in the research centers practice, is important for calcium channel blockers efficiency analysis for chronic renal failure treatment.

2 tbl